Skip to main content

Taysha Gene Therapies, Inc 10-Q for FY2026 Q3

Taysha Gene Therapies, Inc. (TSHA)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 12, 2026

About this 10-Q

Taysha Gene Therapies, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Taysha Gene Therapies said all 12 REVEAL Part A patients gained or regained at least one developmental milestone after TSHA-102. The 17-patient REVEAL pivotal trial has completed dosing, with topline data expected in the first half of 2027. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$0
compared with $0 a year earlier
Net loss
$39.13M
compared with a net loss of $32.73M a year earlier
Diluted EPS
-$0.10
compared with -$0.09 a year earlier